Bicycle Therapeutics PLC
NASDAQ:BCYC

  • LAST PRICE
    23.4600
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    9.3900/ 2
  • Ask / Lots
    29.9900/ 3
  • Open / Previous Close
    --- / 23.4600
  • Day Range
    ---
  • 52 Week Range
    12.5400
    28.6701
  • Volume
    ---

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
BCYC
Bicycle Therapeutics PLC
1.6B
-7.1x
---
NAMS
NewAmsterdam Pharma Company NV
1.6B
-6.8x
---
NTLA
Intellia Therapeutics Inc
1.5B
-2.8x
---
SNDX
Syndax Pharmaceuticals Inc
1.6B
-5.6x
---
CLDX
Celldex Therapeutics Inc
1.7B
-9.3x
---
TARS
Tarsus Pharmaceuticals Inc
1.8B
-10.4x
---
As of 2024-11-05

Company Information

Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating BT8009, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology. Its product candidates also include BT1718 and BT7455.

Contact Information

Headquarters
Blocks A & B, Portway Building, Granta PCAMBRIDGE, United Kingdom CB21 6GS
Phone
122-326-1503
Fax
---

Executives

Non-Executive Chairman of the Board
Pierre Legault
Chief Executive Officer, Executive Director
Kevin Lee
Chief Financial Officer, Principal Financial Officer
Alethia Young
Chief Operating Officer
Alistair Milnes
Chief Technology Officer
Michael Skynner

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$1.6B
Revenue (TTM)
$36.9M
Shares Outstanding
69.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.91
EPS
$-3.28
Book Value
$8.74
P/E Ratio
-7.1x
Price/Sales (TTM)
43.9
Price/Cash Flow (TTM)
---
Operating Margin
-534.98%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.